Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007
Systemic cytokine levels in community-acquired pneumonia and their association with disease severity Source: Eur Respir J 2002; 20: 990-995 Year: 2002
Factors associated with inflammatory cytokine patterns in community-acquired pneumonia Source: Eur Respir J 2011; 37: 393 Year: 2011
Local and systemic cytokine profiles in nonsevere and severe community-acquired pneumonia Source: Eur Respir J 2013; 41: 1378-1385 Year: 2013
Local and systemic cytokine profiles in patients with non-severe and severe community-acquired pneumonia Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012
Corticosteroids in severe pneumonia Source: Eur Respir J 2008; 32: 259-264 Year: 2008
Effect of corticoids on the inflammatory response measured in blood in severe community-acquired pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 461s Year: 2003
Effects of empirical antibacterial therapy on the degree of systemic inflammatory response in patients with severe community-acquired pneumonia (SCAP) Source: Eur Respir J 2003; 22: Suppl. 45, 2s Year: 2003
Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007
Impact of host status, bacteria and antibiotic therapy on systemic inflammatory response syndrome (SIRS) development in community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
Enhanced PMN response in chronic bronchitis and community-acquired pneumonia Source: Eur Respir J 2004; 24 : 772-778 Year: 2004
The clinical significance of serum and bronchoalveoalr lavage inflammatory cytokine in patients with acute respiratory failure due to severe community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 347s Year: 2006
Influence of antibiotic pre-treatment on inflammatory markers in community-acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008
Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015
Effects of glucocorticoids in ventilated piglets with severe pneumonia Source: Eur Respir J 2008; 32: 1037-1046 Year: 2008
Inhaled corticosteroids (ICS), systemic inflammatory response and mortality in community-acquired pneumonia (CAP) Source: Annual Congress 2011 - Severity, comorbidities and outcomes in community-acquired pneumonia Year: 2011
Enhanced neutrophil response in patients with chronic bronchitis and community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 418s Year: 2002
Cytokine responses, microbial etiology and short-term outcome in community-acquired pneumonia Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers Year: 2017
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009
Systemic corticosteroid for treating severe community-acquired pneumonia Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015